Eli Lilly EBITDA 2010-2022 | LLY

Eli Lilly annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Eli Lilly EBITDA for the quarter ending March 31, 2022 was $2.840B, a 88.63% increase year-over-year.
  • Eli Lilly EBITDA for the twelve months ending March 31, 2022 was $9.239B, a 31.55% increase year-over-year.
  • Eli Lilly 2021 annual EBITDA was $7.905B, a 7.08% increase from 2020.
  • Eli Lilly 2020 annual EBITDA was $7.382B, a 18.93% increase from 2019.
  • Eli Lilly 2019 annual EBITDA was $6.207B, a 20.67% increase from 2018.
Eli Lilly Annual EBITDA
(Millions of US $)
2021 $7,905
2020 $7,382
2019 $6,207
2018 $5,144
2017 $3,571
2016 $4,758
2015 $4,117
2014 $4,039
2013 $6,816
2012 $6,196
2011 $6,902
2010 $7,858
2009 $6,885
Eli Lilly Quarterly EBITDA
(Millions of US $)
2022-03-31 $2,840
2021-12-31 $2,363
2021-09-30 $2,264
2021-06-30 $1,773
2021-03-31 $1,506
2020-12-31 $2,360
2020-09-30 $1,637
2020-06-30 $1,521
2020-03-31 $1,864
2019-12-31 $1,741
2019-09-30 $1,719
2019-06-30 $1,746
2019-03-31 $1,002
2018-12-31 $1,246
2018-09-30 $1,759
2018-06-30 $420
2018-03-31 $1,719
2017-12-31 $691
2017-09-30 $915
2017-06-30 $1,596
2017-03-31 $370
2016-12-31 $1,023
2016-09-30 $1,336
2016-06-30 $1,297
2016-03-31 $1,101
2015-12-31 $671
2015-09-30 $1,320
2015-06-30 $1,244
2015-03-31 $883
2014-12-31 $648
2014-09-30 $941
2014-06-30 $1,235
2014-03-31 $1,215
2013-12-31 $1,230
2013-09-30 $1,894
2013-06-30 $1,867
2013-03-31 $1,825
2012-12-31 $1,356
2012-09-30 $1,509
2012-06-30 $1,564
2012-03-31 $1,767
2011-12-31 $1,311
2011-09-30 $1,944
2011-06-30 $1,945
2011-03-31 $1,702
2010-12-31 $1,674
2010-09-30 $2,097
2010-06-30 $2,128
2010-03-31 $1,959
2009-12-31 $926
2009-09-30 $1,996
2009-06-30 $1,903
2009-03-31 $2,060
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.134B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
Novartis AG (NVS) Switzerland $181.123B 13.18
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27